medigraphic.com
ISSN 2007-3194 (Print)
Órgano de difusión oficial del Instituto Materno Infantil del Estado de México

2012, Number 1

<< Back Next >>

Arch Inv Mat Inf 2012; 4 (1)

Test de VPH (captura de híbridos II) en pacientes tratadas con radiofrecuencia

Castaño IM, Hurtado EG

Language: Spanish
References: 33
Page: 13-21
PDF size: 78.05 Kb.


ABSTRACT

Introduction: Human papillomavirus (HPV) is the virus most commonly transmitted through sex. There are methods for detecting molecular biology of this virus. According to the Mexican Official Standard NOM-014-SSA2-1994, molecular tests such as Hybrid Capture and PCR be used as an adjunct to cytology in both the screening and in follow-up after six months after the management. Objective: To determine the percentage of negative HPV test in women treated for preinvasive lesions of the cervix in the Colposcopy Service at the Hospital of Gynecology and Obstetrics, Maternal and Child Health Institute of Mexico State. Material and methods: We included patients with preinvasive lesions of the cervix treated with radiofrequency. At six months were asked HPV test (Hybrid Capture II). Cervical sample was obtained by QUIAGINE Cervical Sampler colposcopically visible in the lesion or defect in the processing area where the injury was. Once processing is performed release and denaturation of nucleic acids. Results: We studied 80 patients with preinvasive lesions of the cervix treated with radiofrequency. Negativization HPV DNA Test HCII at six months was 91.25%. Conclusions: The percentage of negative HPV test achieved in our research is within the accepted level in international standards. Further studies are needed that focus on this issue.


REFERENCES

  1. ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS) group, J Natl Cancer Inst 2000; 92: 397-402.

  2. Kreimer AR, Katki HA, Schiffman M, Wheeler CM, Castle EP. Viral determinants of human papillomavirus persistence following loop electrical excision procedure treatment for cervical intraepithelial neoplasia grade 2 or 3, Cancer Epidemiol Biomarkers Prev 2007; 16: 11-16.

  3. Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G. Human papillomavirus testing in women with mild cytologic atypia, Obstet Gynecol 2000; 95: 821-827.

  4. Bosch FX, de Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality, J Natl Cancer Inst Monogr 2003; 31: 3-13.

  5. Castle PE, Wacholder S, Sherman ME, Lorincz AT, Glass AG, Scott DR et al. Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women, Cancer 2002; 95: 2145-2151.

  6. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7,932 women, Br J Cancer 2001; 84: 1616-1623.

  7. Iftner T, Villa LL. Chapter 12: Human papillomavirus technologies, J Natl Cancer Inst Monogr 2003; 31: 80-88.

  8. Nam K, Chung S, Kim J, Jeon S, Bae D. Factors associated with HPV persistence after conization in patients with negative margins, J Gynecol Oncol 2009; 20: 91-95.

  9. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results, JAMA 1999; 281: 1605-1610.

  10. Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards-Kortum R. Colposcopy for the diagnosis of squamous intraepithelial lesions: A meta-analysis, Obstet Gynecol 1998; 91: 626-631.

  11. Muñoz N, Bosh FX, de Sanjosé S, Herrero R, Castellsaqué X, Shah KV, Snijders PJ, Meijer CJ. International agency for research on cancer multicenter cervical cancer study group. epidemiologic classification of human papillomavirus types associated with cervical cancer, N Engl J Med 2003; 348: 518-527.

  12. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matcher DB. Accuracy of Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review, Ann Int Med 2000; 132: 810-819.

  13. National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses, JAMA 1989; 262: 931-934.

  14. Ordi J, Puig-Tintore LM, Torne A, Sanz S, Esteve R, Romagosa C, Cardesa A. Contribución de la detección de virus del papiloma humano de alto riesgo al estudio de las lesiones premalignas y malignas del cervix uterino, Med Clin (Barc) 2003; 121: 441-445.

  15. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine, N Engl J Med 2002; 347: 1645-1651.

  16. Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S et al. Viral load of HPV and risk of Cin3 or cervical cancer, Lancet 2002; 360: 228-9.

  17. Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WG et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma, Am J Pathol 2000; 157: 1055-62.

  18. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti MC, Wacholder S et al. HPV DNA testing in cervical cancer screening: results from women in a High-risk province of Costa Rica, JAMA 2000; 283: 87-93.

  19. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia, J Natl Cancer Inst Monogr 2003; 31: 14-19.

  20. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC et al. Human papilomavirus infection and time to progression and regression of cervical intraepithelial neoplasia, J Natl Cancer Inst 2003; 95: 1336-43.

  21. Solomon D. Chapter 14: Role of triage testing in cervical cancer screening, J Natl Cancer Inst Monogr 2003; 31: 97-101.

  22. Kinney WK, Manos MM, Hurley LB, Ransley JE. Where’s the high-grade cervical neoplasia? The importance of the minimally abnormal Papanicolaou diagnoses, Obstet Gynecol 1998; 91: 973-976.

  23. Salomon D, Schiffman M, Tarone R, an the ALTS Study Group 2001. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from randomized trial, J Natl Cancer Inst 2001; 93: 293-299.

  24. Staebler A, Sherman ME, Zaino RJ, Ronnett BM. Hormone receptor immunohistochemistry and HPV in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas, Am J Surg Pathol 2002; 26: 998-1006.

  25. Torne A, Ordi J, Puig-Tintore LM, Jou P, Sánchez E, Muntané J, Iglesias X. Determinación del papiloma virus mediante hibridación in situ. Correlación clinicopatológica y virológica en pacientes con lesiones escamosas intraepiteliales del cervix uterino, Med Clin (Barc) 1997; 109: 691-695.

  26. Solomon D, Davey D, Kurman R, Moriarty A, O’Conner D, Prey M et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology, JAMA 2002; 287: 2114-2119.

  27. Torné A, Puig-Tintoré LM, Jou P, Ordi J, Solé M, Sánchez E, Iglesias. X. Concordancia diagnóstica entre citología, colposcopia y pequeña biopsia dirigida en pacientes con lesiones escamosas del cervix uterino, Prog Obstet Ginecol 1996; 39: 520-528.

  28. Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, JAMA 2000; 283: 81-86.

  29. Barrón A, Aranda C, Valenzuela S, Paredes Y, Villegas H. Infección cervical por el virus papiloma humano: genotipificación por hibridación in situ y análisis ultraestructural por microscopia electrónica de transmisión, Perinatol Reprod Hum 2004; 18: 208-216.

  30. Ruiz CJC, Burgos GR, García RL, Sinche SM, Almeida F. Detección y genotipificación del papiloma virus humano, Revista Científica Colposcopia 2008; 1 (1): En: http://www.medicosecuador.com/revistacolposcopia/vol1num1/articulosoriginales/deteccionygenotipificacion.html.

  31. Ordóñez RM, Espinosa AM, Sánchez-González DJ, Armendáriz-Borunda J, Berumen J. Enhanced oncogenicity of Asian-American human papillomavirus 16 is associated with impaired E2 repression of E6/E7 oncogene transcription, J Gen Virol 2004; 85: 1433-1444.

  32. Norma Oficial Mexicana NOM-014-SSA2-1994. Para la prevención, tratamiento y control del cáncer de cuello del útero y de la mama en la atención primaria.

  33. De Luca GD, Alonso JM. Lucero RH, Martín de Civetta MT, Zibelman de Gorodner OL. Genotipificación del virus papiloma humano (HPV) por PCR-RFLP en alteraciones cervicales. Instituto de Medicina Regional UNNE. Chaco. Argentina. En: http://www.unne.edu.ar/Web/cyt/cyt/2002/03-Medicas/M-045.pdf




2020     |     www.medigraphic.com